Search the Newsreel

Sarepta names former AbbVie R&D exec Michael Severino as next CEO

Sarepta Therapeutics has appointed Michael Severino, formerly of Tessera Therapeutics and AbbVie, as its new CEO, succeeding Doug Ingram. Severino takes the helm at a critical juncture as Sarepta awaits two key FDA decisions for its Duchenne muscular dystrophy drugs, Amondys 45 and Vyondys …

AbbVie stock hits all-time high of 261.71 USD

AbbVie Inc. (ABBV) stock has reached a new all-time high of $261.71, reflecting a 40.53% total return over the past year. Despite being considered slightly overvalued by InvestingPro analysis, the company demonstrates strong financial health with 9.5% revenue growth. Upcoming earnings on July 31st …

Is AbbVie Stock a Buy After Its $10.9 Billion Apogee Bet

AbbVie (ABBV) recently acquired Apogee Therapeutics for $10.9 billion, a move that is expected to dilute adjusted EPS until 2032 but aims for a "mega blockbuster" drug, zumilokibart, targeting over $10 billion in peak sales. Despite the near-term dilution, AbbVie stock has largely recovered …

Sarepta names former Abbvie president as CEO as Ingram retires

Sarepta Therapeutics has appointed Michael Severino, former Tessera Therapeutics CEO and a longtime AbbVie executive, as its new chief executive, effective July 28. Severino will succeed Doug Ingram, who is stepping down after leading Sarepta since 2017 but will remain in an advisory role …

How Abbvie Inc. (ABBV) Affects Rotational Strategy Timing

This article from Stock Traders Daily analyzes Abbvie Inc. (ABBV) and its impact on rotational strategy timing. It highlights a neutral sentiment for ABBV across all horizons, suggesting a wait-and-see approach, and identifies no resistance levels above the current price, indicating potential upside. The …

Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth

Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the "Jensen Quality Growth Equity Strategy". A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies …

Is Abbott Stock Attractive After Its Earnings and Guidance Update?

Abbott Laboratories (ABT) reported a stronger second quarter with an earnings beat and raised its full-year profit outlook, driven by growth in medical devices and cancer diagnostics. Despite these positive updates and a diversified business model providing support, the stock's valuation offers limited upside …

FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

Freenome, Inc. Freenome is a biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone. – Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare …

Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson

This Zacks Investment Ideas feature highlights General Motors, Abbott Laboratories, and Johnson & Johnson, all of which posted strong Q2 earnings and raised their guidance. These guidance upgrades are considered a bullish indicator, often leading to positive share reactions and reflecting improving business fundamentals, …

Buy, hold, sell: Aussie Broadband, James Hardie, Macquarie shares

Abbott Laboratories stock trades steadily as diagnostics and medical devices support earnings

Abbott Laboratories' stock (ABT) is trading steadily, supported by diversified revenue streams from diagnostics, medical devices, nutrition, and established pharmaceuticals. Despite a decline in COVID-19 testing revenue, core businesses like continuous glucose monitoring and cardiovascular devices are driving growth, leading to resilient earnings and …

Abbott Laboratories Aktie: 12,51 Milliarden im Quartal

AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback

AbbVie (ABBV) may be 3% undervalued despite a recent setback in the Phase 3 EPCORE DLBCL-1 trial for its drug epcoritamab. The company's diverse pipeline and strong cash generation suggest potential for future growth, with a fair value estimated at $266.89 against a last …

AbbVie stock trades steadily as Humira erosion meets Skyrizi and Rinvoq growth

AbbVie Inc. is managing a transition as its blockbuster drug Humira faces declining sales due to biosimilar competition. The company is actively offsetting this revenue loss with the strong growth of newer immunology drugs, Skyrizi and Rinvoq, which are showing double-digit percentage growth. Investors …

PRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records

Schubert Jonckheer & Kolbe LLP is investigating a data breach impacting Abbott Laboratories and its subsidiary Exact Sciences Corporation. An unauthorized third party, allegedly ShinyHunters, accessed legacy cancer diagnostics systems in July 2026, potentially exfiltrating sensitive patient information including names, contact details, dates of …

Should You Pay Attention To AbbVie Stock's Momentum?

The article poses a question about whether investors should pay attention to AbbVie stock's momentum. However, the provided content is largely navigational, legal disclaimers, and technical limitations of an interactive model, without any actual article text or financial analysis regarding AbbVie. It does not …

Abbott Laboratories (ABT) Could Be 14% Undervalued On Mixed Earnings And Growth Focus

Abbott Laboratories (ABT) is considered 14% undervalued despite mixed Q2 2026 earnings, which showed increased sales but lower net income year-over-year. The company's stock has seen short-term gains, rising 13.9% over 30 days, reflecting a reset in investor expectations and a focus on future …

AbbVie stock may move 4.2% on July 31 earnings report

AbbVie Inc. (NYSE:ABBV) stock is projected to move by 4.2% based on options data ahead of its July 31 earnings release. Historically, the stock's actual movement has often exceeded the implied move from options. The article details past earnings announcement performances, noting instances where …

Abbott Laboratories (ABT) Impulsó Sus Ventas, ¿Sigue Infravalorada?

Abbott Laboratories Revenue Breakdown – NYSE:ABT

Abbott wins dismissal of shareholder lawsuit over 2022 infant formula recall

A federal judge in Chicago has dismissed a lawsuit against Abbott Laboratories that accused the company of defrauding shareholders regarding its 2022 infant formula recall. The judge stated that despite a lengthy complaint, shareholders failed to adequately present claims against Abbott or individual defendants.

ABT|Abbott Laboratories|Kurs:108.442|Änderung %:+0.632

Abbott India Limited Revenue Breakdown – NSE:ABBOTINDIA

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie (ABBV) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended June 2026, with results anticipated on July 31. The consensus EPS estimate is $3.66 per share (+23.2% year-over-year) and revenues are projected at $16.81 billion (+9%). …

CNBC ‘Final Trades’: Netflix, AbbVie, Cerebras Systems - Netflix (NASDAQ:NFLX), CrowdStrike Holdings (NAS

This article summarizes the "Final Trades" segment on CNBC, highlighting stock picks from various financial experts. Recommendations include AbbVie (ABBV) with a raised price target, Transocean (RIG) ahead of earnings, Cerebras Systems (CBRS) due to a new cybersecurity partnership with CrowdStrike (CRWD), and Netflix …

ABT|Abbott Laboratories|Price:107.810|Chg%:-0.150

ABBV|AbbVie Inc|Price:256.910|Chg%:+3.610

AbbVie Inc. (ABBV) shows stable fundamentals and high growth potential, with its valuation considered fairly valued within the Pharmaceuticals industry. The stock is a high dividend payer and exhibits high institutional ownership. While the stock price is expected to trend upwards in the medium …

Abbott Laboratories stock trades steady as diagnostics and medical devices support earnings momentum

Abbott Laboratories' stock (ABT) is trading steadily, supported by diversified revenue streams from diagnostics, medical devices, nutrition, and established pharmaceuticals. Despite a decline in COVID-19 testing revenue, core businesses like continuous glucose monitoring and cardiovascular devices are driving growth, leading to resilient earnings and …

Genmab, AbbVie Clarify Epcoritamab Phase 3 Trial Missed Primary Endpoint

Genmab and AbbVie issued a clarification regarding their Phase 3 EPCORE DLBCL-1 trial, stating that overall survival was the sole U.S. primary endpoint and it was not met. This clarification was deemed necessary due to interpretive ambiguity in earlier disclosures, highlighting the complexities of …

Genmab, AbbVie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

Genmab and AbbVie announced that their lymphoma drug, epcoritamab, did not meet the primary endpoint in a Phase 3 clinical trial. The trial aimed to evaluate the drug's efficacy in patients with diffuse large B-cell lymphoma (DLBCL). This outcome is a setback for the …

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie clarified that overall survival (OS) was the sole U.S. primary endpoint for the Phase 3 EPCORE DLBCL-1 trial, which unfortunately did not meet this endpoint, indicating no statistically significant improvement in OS. The study evaluated epcoritamab in adults with relapsed or …

Epcoritamab U.S. Lymphoma Trial Does Not Meet Survival Endpoint

Genmab and AbbVie announced that their Phase 3 EPCORE® DLBCL-1 trial, evaluating epcoritamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival in the U.S. market. While epcoritamab is already approved under accelerated pathways for similar conditions, …

Abbott Stock And 2 Dividend Ideas For Retirement Income

This article explores three dividend stocks—Abbott Laboratories (ABT), Yü Group (AIM:YU.), and Artesian Resources (ARTN.A)—as potential retirement income sources, especially in light of Social Security reform concerns. It analyzes each company's overview, operations, market cap, and investment considerations, highlighting their strengths and risks for …

AbbVie: Bright Future, But Already Priced In (NYSE:ABBV)

AbbVie Inc. is rated a 'Hold' due to its slight overvaluation and high debt levels, despite strong Q1/26 revenue and free cash flow growth. The company's growth is largely driven by Skyrizi and Rinvoq, with pipeline diversification coming from Neuroscience and the Apogee Therapeutics …

Abbott Faces Joint Spinal Cord Stimulator Lawsuit Filed by 17 Patients

Seventeen patients have filed a joint product liability lawsuit against Abbott Laboratories, alleging that its spinal cord stimulator (SCS) systems were defective, failed to alleviate chronic pain, and caused painful neurological complications. The lawsuit claims that Abbott misrepresented the safety and approval status of …

Receita da Abbott atinge US$ 12,59 bilhões no 2T2026